Read about the new Rx products featured in October 2016.
Marketed by: Eli Lilly and Company
Indication: The FDA has approved Basaglar (insulin glargine injection), a long-acting human insulin analog, for improving glycemic control in adults and pediatric patients with type 1 diabetes mellitus, and in adults with type 2 diabetes mellitus. The dosage should be individualized based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. Basaglar should be administered subcutaneously once daily at any time of day, but at the same time every day.
Dosage Form: Injection: 100 units/ mL (U-100) in 3-mL prefilled Basaglar KwikPen delivery device
For More Information: basaglar.com
Marketed by:Boehringer Ingelheim Pharmaceuticals, Inc
Indication:The FDA has approved Jentadueto, a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. The starting dose of Jentadueto should be individualized based on the patient’s current regimen. The maximum recommended dose is 2.5 mg linagliptin/1000 mg metformin twice daily.
Dosage Form:Tablets (linagliptin/metformin hydrochloride): 2.5/500, 2.5/850, and 2.5/1000 mg
For More Information:hcp.jentadueto.com
Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc
Indication: Synjardy (empagliflozin and metformin hydrochloride) is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with both empagliflozin and metformin. The starting dose should be individualized based on the patient’s current regimen. The maximum recommended dose is 12.5 mg empagliflozin/1000 mg metformin twice daily.
Dosage Form: Tablets: 5 mg/500 mg, 5 mg/1000 mg, and 12.5 mg/500 mg, and 12.5 mg/1000 mg
For More Information: boehringer-ingelheim.com